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Abstract 
In this study, we demonstrate that N
6
-isopenthenyladenosine, which essentially is a plant cytokinin-like 
compound, exerts a potent and selective antiviral effect on the replication of human enterovirus 71 with 
an EC50 of 1.0 ± 0.2 µM and a selectivity index (SI) of 5.7. The synthesis of analogs with modification of 
the N
6
-position did not result in a lower EC50 value. However, in particular with the synthesis of N
6
-(5-
hexene-2-yne-1-yl)adenosine (EC50 = 4.3 ± 1.5µM), the selectivity index was significantly increased: 
because of a reduction in the adverse effect of this compound on the host cells, an SI >101 could be 
calculated. With this study, we for the first time provide proof that a compound class that is based on the 
plant cytokinin skeleton offers an interesting starting point for the development of novel antivirals against 
mammalian viruses, in the present context in particular against enterovirus 71. 
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1. Introduction 
Common natural isoprenoid cytokinins are N
6
-isopentenyladenine, trans- and cis-zeatin, and 
dihydrozeatin. The first step in isoprenoid cytokinin biosynthesis is carried out by the adenosine 
phosphate isopentenyltransferase (EC 2.5.1.27), which catalyzes the N
6
-prenylation of adenosine 5′- 
(mono-, di-, or tri-) phosphates with 3,3-dimethylallyldiphosphate [1]. The resulting nucleotides are 
readily dephosphorylated to their corresponding nucleoside derivatives. These in turn serve as substrate 
for two other enzymes, namely adenosine nucleosidase (EC 3.2.2.7) and purine nucleoside phosphorylase 
*Manuscript
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(EC 2.4.2.1), which convert the cytokinin nucleosides into their cytokinin bases. Accordingly, to these 
transformations N
6
-substituted adenines and adenosines might have similar cytokinin activities [1]. 
 
Several N
6
-substituted adenosines, such as N
6
-isopentenyladenosine, N
6
-methyladenosine, and some 
others have been detected in, amongst others, tRNA [2]. Cytokinin ribosides were found to inhibit the 
growth of mammalian neoplastic cells in vitro [3,4], and, in limited clinical trials in the 1970’s, N6-
isopentenyladenosine showed some antitumor chemotherapeutic effect [5]. These findings initiated an 
interest to synthesize novel N
6
-adenosine analogs in an attempt to identify compounds with enhance 
antitumor activity. However, biological evaluation of a wide variety of such derivatives did not yield 
compounds with activity higher than that of N
6
-isopentenyladenosine itself [6]. 
Nonetheless, encouraged by the fact that N
6
-substituted adenosines have been shown to elicit biological 
activity in mammalian assay systems for malaria [7], African sleeping sickness [8], toxoplasmosis [9], 
and some others, we decided to explore the potential of N
6
-isopentenyladenosine and derivatives as 
inhibitors of virus replication. 
 
2. Results and discussion 
 
2.1. Chemistry 
  
Recently, we developed a new and versatile method for the preparation of N
6
-adenosine derivatives by 
regioselective N
6
-alkylation of N
6
-acetyl-2′,3′,5′-tri-O-acetyladenosine [10,11]. Alkylation can be 
performed with alkyl halides in basic conditions (K2CO3 in DMF or DBU in MeCN) and alternatively 
with alcohols using Mitsunobu protocol. Compounds 2a-c were synthesized by alkylation of tetraacetate 
1 with appropriate alkyl halides (Scheme 1, method A) and they were deprotected with ammonia in 
methanol according to well-established procedures reported in the literature. 
In other cases, tetraacetate 1 was transformed into nucleosides 2d-k using the Mitsunobu protocol 
(Scheme 1, method B). Although the Mitsunobu coupling promoted with Ph3P and DEAD (diethyl 
azodicarboxylate) is a very popular mild chemical transformation that occurs under essentially neutral 
conditions, it produces at least equivalent amounts of Ph3PO and (NHCOOEt)2. Scrupulosity and patience 
is necessary to isolate pure acetates 2 by column chromatography. Some simplification can be achieved 
when crude acetates 2 are subjected to deacylation and free nucleosides are isolated by chromatography. 
3 
 
 
Scheme 1. Synthesis of adenosine derivatives with unsaturated N
6
-substituents. Reagents and conditions: 
(i) Method A: RX, K2CO3, DMF, room temperature, 16 h; (ii) Method B: ROH, Ph3P, DEAD, THF, 
room temperature, 20 h; (iii) 7M NH3 in MeOH, room temperature, 48 h; (iv) 4M PrNH2 in MeOH, room 
temperature, 24 h; (v) 0.5M НСl, 100°С, 8 h; (vi) enzymatic phosphorolysis (E. Coli PNP, KH2PO4, pH 
7.5). 
 
Deacylation with 7M NH3 in methanol at room temperature proceeded completely during 48 h. However, 
the rate of deprotection of N-acetyl and O-acetyl groups in nucleosides 2 are quite different: the first one 
is much more stable and, as a result, an additional amount of acetamide was formed under deblocking 
conditions. Acetamide caused some difficulties in the purification of the final products using column 
chromatography on silica gel, because it was often eluted together with nucleosides 3. 
We have also tried to use 0.1M MeONa in MeOH at room temperature for removal of acetyl groups. 
After 30 minutes, we were able to isolate N
6
-acetyl derivatives of 3 in good yields and their structure was 
confirmed by NMR and MS methods. Prolonged treatment results in substantial decomposition of the 
desired products. 
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Finally, we found that the use 4M PrNH2 in MeOH [12] at room temperature for one day is the method of 
choice for the preparation of nucleosides 3. The formed N-propylacetamide have higher mobility on silica 
gel than the desired nucleosides 3. 
N
6
-Substituted adenine derivatives 4b-c were obtained by acid hydrolysis of the nucleosides 3b-c. The 
treatment of corresponding nucleosides with 0.5M НСl at 100°С leads to cleavage of the glycoside bond 
and removal of N-acetyl group. Unfortunately, this method was not applicable to isoprenoid derivatives 
due to the side reactions [13,14]. Isopentenyladenine (4a) was obtained via the enzymatic phosphorolysis 
of 3a in the presence of recombinant purine nucleoside phosphorylase in KH2PO4 buffer (pH 7.5) [10]. 
The structure of all synthesized compounds was confirmed by NMR and MS methods. 
Among the synthesized derivatives, N
6
-acetyl-N
6
-propargyl-2′,3′,5′-tri-O-acetyladenosine (2c) may be 
used for introduction of new structural motifs in the adenine moiety according to Scheme 2.  
No literature examples of allylation of acetylenic nucleic base derivatives were found, though successful 
examples carried out on simple alkynes are available [15,16,17]. We found that reaction of allyl bromide 
and 3,3-dimethylallyl bromide with compound 2c can be carried out in the presence of CuCl and a base at 
ambient temperature affording 5 and 6 in 70 – 80 % yield. It is noteworthy that no reaction occurred when 
allylic halides were substituted with methyl iodide or benzyl bromide. This can be a piece of evidence 
that the mechanism of acetylenic allylation reaction is more complicated than it was suggested by Grushin 
and Alper [15], since it is limited only to allylic halides. Obviously, the participation of η3-allylic 
complex should also be taken into consideration. The participation of binuclear copper species is also 
highly probable in a way similar to Cu (I) catalyzed [3+2] cycloaddition of azides to acetylenes [18]. 
 
.  
Scheme 2. Allylation of acetylenic adenosine derivative 1. Reagents and conditions: (i) R2C=CHCH2Br, 
K2CO3, CuCl, BuN4Br, DMF, room temperature, 14 h; (ii) 7M NH3 in MeOH, room temperature, 48 h. 
 
The reaction of 2c with allylbromide and 3,3-dimethylallylbromide is to be carried out at ambient 
conditions but in anaerobic (N2) atmosphere to observe a sufficient increase in yields. We were unable to 
monitor both reactions by TLC on silica gel plates because in the wide range of the used solvents, the 
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starting compound 2c and the products 5 or 6 have quite the same mobility. To ensure the complete 
consumption of 2c and for simplification of chromatographic isolation of 5 and 6, the reaction mixtures, 
after stirring for 14 h in N2 atmosphere, were additionally stirred for 6-8 h in air. This causes the 
oxidation of the unreacted initial compound 2c with the formation of more polar products, thus 
simplifying the isolation procedure. After removal of acetyl groups by ammonolysis of peracetylated 
compounds 5 and 6, free nucleosides 7 and 8 can be isolated in good yields. 
 
Table 1. 
1
H-NMR data for compounds 5-8. 
H atom 5 7 6 8 
1-H 
t, 2H 
 = 5.1 ppm 
5
J1-H,4-H = 2.2 Hz 
s (broad), 2H 
 = 4.29 ppm 
 
t, 2H 
 = 5.05 ppm 
5
J1-H,4-H = 2.2 Hz 
s (broad), 2H 
 = 4.25 ppm 
 
4-H 
m, 2H 
 = 2.83 ppm 
5
J4-H,1-H = 2.2 Hz 
4
J4-H,6-H = 1.6 Hz 
4
J4-H,6-H = 2 Hz 
3
J4-H,5-H = 5.1 Hz 
m, 2H 
 = 2.92 ppm 
 
4
J4-H,6-H = 1.4 Hz 
4
J4-H,6-H = 1.7 Hz 
3
J4-H,5-H = 5 Hz 
m, 2H 
 = 2.74 ppm 
5
J4-H,1-H = 2.2 Hz 
3
J4-H,5-H = 6.9 Hz 
d, 2H 
 = 2.85 ppm 
 
3
J4-H,5-H = 6.8 Hz 
5-H 
ddt, 1H 
 = 5.65 ppm 
3
J5-H,4-H = 5.1 Hz 
3
J5-H,6-H = 10 Hz 
3
J5-H,6-H = 17.1 Hz 
ddt, 1H 
 = 5.73 ppm 
3
J5-H,4-H = 5 Hz 
3
J5-H,6-H = 10 Hz 
3
J5-H,6-H = 17.3 Hz 
m, 1H 
 = 5.00 ppm 
4
J5-H,7-H = 1 Hz 
3
J5-H,4-H = 6.9 Hz 
 
m, 1H 
 = 5.09 ppm 
4
J5-H,7-H = 1 Hz 
3
J5-H,4-H = 6.8 Hz 
 
6-Htrans* 
ddt, 1H 
 = 4.97 ppm 
4
J6-H,4-H = 1.6 Hz 
3
J6-H,5-H = 10 Hz 
2
J6-H,6-H = 1.7 Hz 
ddt, 1H 
 = 4.57 ppm 
4
J6-H,4-H = 1.7 Hz 
3
J6-H,5-H = 10 Hz 
2
J6-H,6-H = 1.7 Hz 
  
6-Hcis* 
ddt, 1H 
 = 5.06 ppm 
4
J6-H,4-H = 2 Hz 
3
J6-H,5-H = 17.1 Hz 
2
J6-H,6-H = 1.7 Hz 
ddt, 1H 
 = 5.21 ppm 
4
J6-H,4-H = 1.4 Hz 
3
J6-H,5-H = 17.3 Hz 
2
J6-H,6-H = 1.7 Hz 
  
7-H 
  d, 3H 
 = 1.62 ppm 
4
J7-H,5-H = 1 Hz 
d, 3H 
 = 1.64 ppm 
4
J7-H,5-H = 1 Hz 
8-H 
  s, 3H 
 = 1.49 ppm 
s, 3H 
 = 1.55 ppm 
*relatively to the alkyl substituent at double bond 
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Fig. 1. Numeration of carbon atoms in N
6
-substituents of compounds 5 and 6. 
 
The structure of the side chain of the compounds was unambiguously assigned by 
1
H NMR spectral data 
(the numeration of side chain carbon atoms is depicted in Figure 1. Long-range spin-spin coupling 
constants were observed (Table 1). In compounds 5 and 6, the 1-CH2 groups appears as triplets with 
5
J = 
2.2 Hz. In the free nucleosides 7 and 8, significant broadening of the 1-CH2 signals is observed. Such 
effect is general for free N
6
-substituted nucleosides. A possible explanation can be found in the literature 
and is ascribed to ‘a chemical exchange process connected to the restricted conformational change’ 
[19,20]. As a result, spin-spin coupling between 1-CH2 and 4-CH2 is not detectable. Nevertheless, the sets 
of constants for other hydrogen atoms remain the same as for acetylated nucleosides 5 and 6 (see Table 
1). Thus, no principle structural changes of N
6
-residues occurred during deprotection. The chemical purity 
of 7 and 8 was established to be higher than 99 % on the basis of LC-MS analysis. 
 
2.2. Biological activity 
In a first round, the compounds were evaluated for their potential as inhibitors of virus replication in cell-
based assays for hepatitis C virus (HCV, replicon-based assay), chikungunya virus (CHIKV, virus-cell-
based assay) and enterovirus 71 (EV71, virus-cell-based assay). No antiviral activity was observed in the 
assays for HCV and CHIKV. In contrast, a clear cell protective effect was apparent in the EV71 assay for 
compounds 3a, 3b, 3e, 3j, 3k, and 7, for which an EC50 value could be derived from the dose-response 
curves (Table 2). This value represents the concentration of compound that induces a cell protective effect 
of 50% and is indicative of the antiviral potency of the compound. In parallel, also uninfected cells were 
treated with the compounds to quantify the adverse effect of treatment on host cell metabolism. From 
these dose-response curves, CC50 values equaling the concentration of compound that reduces overall 
host cell metabolism by 50%, are calculated. From both values, the selectivity index (SI= CC50/EC50) can 
be derived, a value that is indicative for the therapeutic window of a particular compound in this assay 
(the larger the SI, the larger the therapeutic window). However, a cell protective effect that is obtained in 
a virus-cell-based assay does not necessarily prove that a compound selectively inhibits virus replication. 
Therefore, all assay wells with a cytoprotective effect were inspected by microscope for minor signs of 
virus-induced cell death, or for treatment-induced host cell or monolayer abnormalities. Only compounds 
for which the cells at least at one concentration of compound resemble the untreated, uninfected control 
cells are considered as selective inhibitors of EV71 virus replication. Compound 3a proved to be the most 
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potent compound of this series (EC50 of 1.0 ± 0.2 µM) while compound 7 was the most selective 
compound (SI>101). Both matched the selection criteria for a selective inhibitor of EV71 replication as 
outlined above, and were selected for further evaluation. The N
6
-substituted adenines 4a-c do not elicit an 
antiviral effect in this assay, which indicates that the ribofuranose residue is most likely essential for 
antiviral activity. 
 
Table 2. Antiviral effect on the replication of EV71 strain BrCr in RD cells. 
 Compound name CC50 ± SD
a b
 EC50 ± SD
a b
 SI 
3a N
6
-isopenthenyladenosine 5.7 ± 0.3 1.0 ± 0.2 5.7 
4a N
6
-isopenthenyladenine ND >492 ND 
3b N
6
-allyladenosine 78 ± 20 7.1 ± 1.6 11 
4b N
6
-allyladenine ND >571 ND 
3c N
6
-propargyladenosine 166 ± 15 >166 ND 
4c N
6
-propargyladenine ND >577 ND 
3d N
6
-(4-hydroxy-2-butynyl) 
adenosine 
ND >298 ND 
3e N
6
-(Z)-(4-hydroxy-2-butenyl) 
adenosine 
122 ± 25 4.7 ± 0.7 26 
3f N
6
-geranyladenosine 174 ± 10 >124 NA 
3g N
6
-neryladenosine >372 >124 NA 
3h N
6
-(S)-(-)-perillyladenosine 307 ± 7 >125 NA 
3i N
6
-(1R)-(-)-myrtenyladenosine >374 >125 NA 
3j N
6
-cyclopropylmethyladenosine 22 ± 3 4.6 ± 0.8 5 
3k N
6
-(tetrahydropyran-2-methyl) 
adenosine 
>274 33 ± 5 >8 
7 N
6
-(5-hexene-2-yne-1-
yl)adenosine 
>434 4.3 ± 1.5 >101 
8 N
6
-(2-methylhept-2-en-4-yne-1-
yl) adenosine 
>402 >335 NA 
a
 All values are in μM and are based on at least three independent dose-response curves. 
b 
On rhabdomyosarcoma (RD) cells 
c 
Selectivity Index (SI); SI=CC50/EC50  
ND = Not Determined; NA = Not Active within tested range 
 
In a second round, the antiviral effect of compound 3a and 7 was evaluated in virus-cell-based assays for 
a panel of other enteroviruses. Interestingly, except for a very faint cell protective effect in the assay for 
echovirus 11 (ECHO11, EC50=230 ± 45 µM), no antiviral activity was observed against any of the other 
viruses. This indicates that the antiviral activity of this compound class is most likely very selective for 
enterovirus 71 (Table 3). 
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Table 3. Antiviral effect of 3a and 7 against a selection of enteroviruses. 
Virus Type Strain 
EC50 ± SD
a
 
3a  7  
EV 71 BrCr 1.0 ± 0.2 4.3 ± 1.5 
PV 
1 
Sabin 
>298 >362 
2 >298 >290 
3 >298 >290 
CV B3 Nancy >298 >290 
ECHO 11 Gregory >224 230 ± 45 
hRV 
2 
/ 
>298 >290 
14 >298 >290 
a All values are in μM and are based on at least three independent dose-response curves. EV = enterovirus, PV = poliovirus, 
CV = Coxsackievirus, ECHO = echovirus, hRV = human rhinovirus 
 
To confirm that the compounds are selective inhibitors for EV71, their antiviral effect was evaluated in 
virus-cell-based assays for a panel of clinical isolates of EV71 that belong to different EV71 genogroups 
(Table 4). Compound 3a proved to be equipotent against all viruses of this panel, while for 7, the activity 
ranged from 0.9 ± 1.8µM for EV71 strain H08300 461 #812 (genogroup C2) to 17 ± 4 µM for EV71 
strain TW/70902/08 (genogroup B5). Also the other virus isolate that belongs to genogroup B5 appeared 
to be less sensitive to the antiviral effect of this compound. Because all EV71 assays have been conducted 
using RD (rhabdomyosarcoma) cells, these results may indicate that the compound most likely has a 
mechanism of action that also involves a specific viral protein rather than only a cellular factor. 
 
Table 4. Antiviral effect of 3a and 7 against a selection of EV71 clinical isolates.  
Genogroup Strain Genbank 
EC50 ± SD
b
 
3a  7  
B2 11316 AB575927 2.0 ± 0.1 8.0 ± 2.0 
B5 TW/96016/08 GQ231942 2.3 ± 0.6 12 ± 3 
TW/70902/08 GQ231936 2.5 ± 0.5 17 ± 4 
C2 H08300 461/812 ― 1.2 ± 0.2 0.9 ± 1.8 
C4 TW/1956/05 GQ231926 1.5 ± 0.2 3.9 ± 1.1 
TW/2429/04 GQ231927 1.4 ± 0.5 4.5 ± 1.3 
a All values are in μM and are based on at least three independent dose-response curves. 
 
Investigation of the structure of the compounds in the context of their antiviral activity (structure-activity 
relationship analysis, SAR), a clear indication is obtained that the potency of the compounds strictly 
depends on the size of the N
6
-substituent and that a ribofuranose residue can be considered as essential for 
antiviral activity (adenine derivatives 4a-c are inactive). 
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3. Conclusions 
 
In the present study, we reported on the synthesis of N
6
-isopentenyladenosine analogues and 
demonstrated that these cytokinin-like compounds have potential as inhibitors of the replication of EV71 
in a mammalian bio-assay. To obtain a deeper insight into the structure-activity relationship of these 
compounds against EV71, additional sets should be prepared, which hopefully will allow the 
identification of a compound with a large window of selectivity. The availability of such a compound will 
be essential to initiate studies into the precise molecular mechanism of action by which enterovirus 71 
replication is inhibited. 
 
4. Experimental section  
4.1. General 
The solvents and materials were reagent grade and were used without additional purification. Column 
chromatography was performed on silica gel (Kieselgel 60 Merck, 0.063-0.200 mm). TLC was performed 
on Alugram SIL G/UV254 (Macherey-Nagel) with UV visualization. Melting points were determined on 
a Electrothermal apparatus and are uncorrected. 
1
H and 
13
C (with complete proton decoupling) NMR 
spectra were recorded on Bruker AMX 400 NMR instrument at 300K. 
1
H-NMR-spectra were recorded at 
400 MHz and 
13
C-NMR-spectra at 100 MHz. Chemical shifts in ppm were measured relative to the 
residual solvent signals as internal standards (CDCl3, 
1
H: 7.26 ppm, 
13
C: 77.1 ppm; DMSO-d6, 
1
H: 2.50 
ppm, 
13
C: 39.5 ppm) [21]. Spin-spin coupling constants (J) are given in Hz. Double resonance technique 
was applied for assigning the resonances. High resolution mass spectra (HRMS) were measured on a 
Bruker micrOTOF II instrument using electrospray ionization (ESI) [22]. The measurements were done in 
a positive ion mode (interface capillary voltage – 4500 V) or in a negative ion mode (3200 V); mass range 
from m/z 50 to m/z 3000 Da; external or internal calibration was done with Electrospray Calibrant 
Solution (Fluka). A syringe injection was used for solutions in acetonitrile, methanol, or water (flow rate 
3 L/min). Nitrogen was applied as a dry gas; interface temperature was set at 180C. LC-MS analysis 
was performed on a Surveyor MSQ instrument (Thermo Finnigan, USA), operating in APCI (atmospheric 
pressure chemical ionization) mode with detection of positive and negative ions, and equipped with Onyx 
Monollithic C18 25×4.6 mm Part No CHO-7645 column. The eluent was 0.1% HCOOH in water with a 
gradient of solution in MeCN. Chromatographic peaks were detected simultaneously with ELSD 
(evaporative light scattering detector), PAD (photodiode array detector), and TIC (total ion current) 
detector. In all cases, only one peak was revealed and the chromatographic purity of compounds was 
more than 99%. 
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4.2. Typical procedure for alkylation of tetraacetate 1 in DMF in the presence of K2CO3 (Method A) 
To a stirred mixture of tetraacetate 1 (500 mg, 1.15 mmol), K2CO3 (0.32 g, 2.3 mmol) in 5 ml of DMF in 
one portion alkyl bromide (1.4 mmol) was added at room temperature. The reaction was monitored by 
TLC. After stirring for 20 h at ambient temperature, the conversion was completed. The reaction mixture 
was diluted with AcOEt and the solution was washed with brine (3×20 ml). The extract was dried over 
Na2SO4 and evaporated. The residue was applied to column chromatography on silica gel. 
 
4.2.1. N
6
-Acetyl-N
6
-isopentenyl-2′,3′,5′-tri-O-acetyladenosine (2a) 
A commercial isopentenyl bromide was used for the reaction. The yield of 2a was 410 mg (67%) as a 
foam; Rf 0.41 (CH2Cl2-EtOH, 25:1). 
1
H NMR (400 MHz, CDCl3):  = 1.61 (s, 6Н, Ме), 2.10 (s, 3H, AcO), 
2.13 (s, 3H, AcO), 2.16 (s, 3H, AcO), 2.28 (s, 3H, AcN), 4.39 (dd, 1H, J5′b,5′a = 12.9, J5′b,4′ = 5.2, H-5′b), 
4.45-4.49 (m, 2H, H-5′a + H-4′), 4.84 (d, 2Н, J = 6.7, NCH2), 5.22-5.26 (m, 1Н, СН2СН=С), 5.69 (dd, 
1H, J3′,4′ = 4.8, J3′,2′ = 5.6, H-3′), 5.96 (dd, 1H, J2′,3′ = 5.6, J2′,1′ = 5.0, H-2′), 6.23 (d, 1H, J1′,2′ = 5.0, H-1′), 
8.19 (s, 1H, H-2), 8.79 (s, 1H, H-8). 
 
4.2.2. N
6
-Acetyl-N
6
-allyl-2′,3′,5′-tri-O-acetyladenosine (2b)  
A commercial allyl bromide was used for the reaction. The yield of 2b (420 mg, 77%) as a foam; Rf 0.58 
(CH2Cl2-EtOH, 25:1). 
1
H NMR (400 MHz, CDCl3):  = 2.10 (s, 3H, AcO), 2.12 (s, 3H, AcO), 2.15 (s, 
3H, AcO), 2.32 (s, 3H, AcN), 4.39 (dd, 1H, J5′b,5′a = 12.8, J5′b,4′ = 5.2, H-5′b), 4.46 (dd, 1H, J5′a,5′b = 12.8, 
J5′a,4′ = 3.0, H-5′a), 4.47 (ddd, 1H, J4′,5′b = 5.2, J5′a,4′ = 3.0, J4′,3′ = 4.9, H-4′), 4.88 (d, 1Н, 
3
J = 5.1, NCH2), 
5.04 (dd, 1Н, 2J = 1.0, 3J = 10.3, С=СН-cis), 5.17 (dd, 2J = 1.0, 3J = 17.2, С=СН-trans), 5.69 (dd, 1H, J3′,4′ 
= 4.9, J3′,2′ = 5.4, H-3′), 5.89 (ddd, 
3
J = 5.1, 10.3 and 17.2, СН2СН=С), 5.96 (dd, 1H, J2′,3′ = 5.4, J2′,1′ = 
5.0, H-2′), 6.23 (d, 1H, J1′,2′ = 5.0, H-1′), 8.19 (s, 1H, H-2), 8.78 (s, 1H, H-8). 
 
4.2.3. N
6
-Acetyl-N
6
-propargyl-2′,3′,5′-tri-O-acetyladenosine (2c) 
A commercial solution of propargyl bromide in toluene (80% wt) was used for the reaction. The yield of 
2c was 463 mg (85%) as a foam; Rf  0.42 (CH2Cl2-EtOH, 25:1). 
1
H NMR (400 MHz, CDCl3):  = 2.10 (s, 
3H, AcO), 2.12 (t, 1H, J = 2.5, HC≡C), 2.13 (s, 3H, AcO), 2.16 (s, 3H, AcO), 2.39 (s, 3H, AcN), 4.40 
(dd, 1H, J5′b,5′a = 12.9, J5′b,4′ = 5.2, H-5′b), 4.47 (dd, 1H, J5′a,5′b = 12.9, J5′a,4′ = 3.1, H-5′a), 4.48 (ddd, 1H, 
J4′,5′b = 5.2, J4′,5′a = 3.1, J4′,3′ = 4.8, H-4′), 5.10 (d, 2H, J = 2.5, CH2N,) 5.68 (dd, 1H, J3′,4′ = 4.8, J3′,2′ = 5.6, 
H-3′), 5.97 (dd, 1H, J2′,3′ = 5.6, J2′,1′ = 5.0, H-2′), 6.25 (d, 1H, J1′,2′ = 5.0, H-1′), 8.22 (s, 1H, H-2), 8.82 (s, 
1H, H-8). 
 
4.3. N
6
-Isopentenyladenosine (3a) 
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The tetraacetate 2a (500 mg, 0.99 mmol) was dissolved in 7M NH3 in MeOH (3 ml, 21 mmol) and the 
solution was left for 48 h at ambient temperature. The final reaction mixture was evaporated in vacuum 
and the residue was crystallized from water. The product was dried in vacuum over P2O5. 
The yield of 3a was 124 mg, (33 %) as a white powder; Rf 0.45 (CH2Cl2- EtOH, 4:1). mp 130-132
o
C 
(H2O); Lit.: Mp 134-136
o
C [14]. 
1
H NMR (400 MHz, DMSO-d6):  = 1.66 (s, 3H, Me), 1.69 (s, 3H, Me), 
3.55 (ddd, 1H, J5′b,5′a = 12.1, J5′b,4′ = 3.0, J5′b,OH = 7.9, H-5′b), 3.67 (ddd, 1H, J5′a,5′b = 12.1, J5′a,4′ = 3.6, 
J5′a,OH = 4.6, H-5′a), 3.96 (ddd, 1H, J4′,5′b = 3.0, J4′,5′a = 3.6, J4′,3′ = 2.8, H-4′), 4.14 (ddd, 1H, J3′,4′ = 2.8, 
J3′,2′ = 5.3, J3′,OH = 4.8, H-3′), 4.08 (br s, 2H, NCH2C), 4.60 (ddd, 1H, J2′,3′ = 5.3, J2′,1′ = 6.0, J2′,OH = 6.2, 
H-2′), 5.16 (d, 1H, JOH,3′ = 4.8, 3′-OH, exchangeable with D2O), 5.30 (dd, 1H, JOH,5′b = 7.9, JOH,5′a = 4.6, 
5′-OH, exchangeable with D2O), 5.37-5.47 (m, 2H, JOH,2′ = 6.2, CCH=C, 2′-OH, exchangeable with D2O), 
5.87 (d, 1H, J1′,2′ = 6.0, H-1′), 7.82 (br s, 1H, NH, exchangeable with D2O), 8.19 (br s, 1H, H-2), 8.32 (s, 
1H, H-8). 
13
C NMR (100 MHz, DMSO-d6):  = 18.48 (Me), 26.05 (Me), 38.57 (CH2N), 62.24 (C-5'), 
71.22 (C-3'), 74.24 (C-2'), 86.59 (C-4'), 88.82 (C-1'), 120.13 (C-5), 121.76 (CH=), 135.44 (=CMe2), 
140.52 (C-8), 148.77 (C-4), 153.17 (C-2), 154.97 (C-6). MS (APCI): m/z [M+H
+
] calculated 
[C15H22N5O4] 336.17, found 336.23; m/z [M-H
‒
+HCOOH] calculated [C16H22N5O6] 380.16, found 
380.20.  
 
4.4. N
6
-Allyladenosine (3b) 
Tetraacetate 2b (400 mg, 0.841 mmol) was dissolved in 7M NH3 in MeOH (2.4 ml, 16.8 mmol) and the 
solution was left for 48 h at ambient temperature. The precipitate formed was filtered off and washed with 
ether (10 ml). The product was dried in vacuum over P2O5. The yield of 3b was 182 mg (70%) as a white 
powder; Rf 0.25 (CH2Cl2 – EtOH, 9:1). mp 165-167
 o
C (MeOH); Lit.: Mp 167
o
C [23]. 
1
H NMR (400 
MHz, DMSO-d6): 3.56 (m, 1H, H-5′b), 3.66 (m 1H, H-5′a), 3.97 (m 1H, = 2.8, H-4′), 4.15 br s CH2N, H-
3′), 4.62 (m, 1H, OH), 5.05 (d, J = 10.3, С=СН-cis), 5.13 (m, 1H, OH), 5.15 (d, J = 17.0, С=СН-trans), 
5.34 (m, 1H, H-2′), 5.40 (m, 1H, OH), 5.94-6.13 (m, 2H, overlapping signals of СН2СН=С and H-1′), 
7.98 (br s, 1Н, NH), 8.20 (s, 1H, H-2), 8.34 (s, 1H, H-8). 13C NMR (100 MHz, DMSO-d6):  = 33.56 
(NCH2), 61.66 (C-5'), 70.64 (C-3'), 73.49 (C-2'), 85.89 (C-4'), 87.95 (C-1'), 115.02 (CH=), 118.75 (C-5), 
135.60 (=CH2), 139.78 (C8), 152.30 (C-2), 154.49 (C-6). HRMS: m/z [M+H]
+ 
calculated [C13H18N5O4] 
308.1353, found 308.1357; m/z [M+Na]
+ 
calculated [C13H17N5O4Na] 330.1173, found 330.1176. 
 
4.5. N
6
-Propargyladenosine (3c) 
The tetraacetate 2c (500 mg, 1.06 mmol) was dissolved in 7M NH3 in MeOH (3 ml, 21 mmol) and the 
solution was left for 48 h at ambient temperature. The final reaction mixture was evaporated in vacuum 
and the residue was crystallized from EtOH – H2O. The product was dried in vacuum over P2O5. 
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The yield of 3c was 145 mg (41%) as a white powder; Rf 0.33 (CH2Cl2-EtOH, 9:1). mp 171-174
o
C (EtOH 
- H2O); Lit.: Mp 169
o
C [23]. 
1
H NMR (400 MHz, DMSO-d6):  = 3.01 (t, 1H, J = 2.3, HC≡C), 3.56 (ddd, 
1H, J5′b,5′a = 12.0, J5′b,4′ = 3.7, J5′b,OH = 7.2, H-5′b), 3.68 (ddd, 1H, J5′a,5′b = 12.0, J5′a,4′ = 3.9, J5′a,OH = 4.3, 
H-5′a), 3.97 (ddd, 1H, J4′,5′b = 3.7, J4′,5′a = 3.9, J4′,3′ = 2.8, H-4′), 4.16 (ddd, 1H, J3′,4′ = 2.8, J3′,2′ = 5.0, J3′,OH 
= 4.7, H-3′), 4.29 (br s, 2H, NCH2Ph), 4.60 (ddd, 1H, J2′,3′ = 5.0, J2′,1′ = 5.9, J2′,OH = 6.2, H-2′), 5.14 (d, 
1H, JOH,3′ = 4.7, 3′-OH, exchangeable with D2O), 5.28(dd, 1H, JOH,5′b = 7.2, JOH,5′a = 4.3, 5′-OH, 
exchangeable with D2O), 5.41 (d, 1H, JOH,2′ = 6.2, 2′-OH, exchangeable with D2O), 5.90 (d, 1H, J1′,2′ = 
5.9, H-1′), 8.18 (br s, 1H, NH, exchangeable with D2O), 8.28 (br s, 1H, H-2), 8.39 (s, 1H, H-8). 
13
C NMR 
(100 MHz, DMSO-d6): δ = 29.38 (CH2N), 61.69 (C-5'), 70.67 (C-3'), 72.47 (HC≡), 73.66 (C-2'), 81.88 (-
C≡), 85.94 (C-4'), 88.03 (C-1'), 119.93 (C-5), 140.25 (C-8), 148.88 (C-4), 152.32 (C-2), 154.07 (C-6). MS 
(APCI): m/z [M+H
+
] calculated [C13H16N5O4] 306.12, found 306.20; m/z [M-H
-
+HCOOH] calculated 
[C14H16N5O6] 350.11, found 350.14. 
 
4.6. Typical procedure for preparation of nucleosides 3d-k by Mitsunobu reaction of tetraacetate 1 with 
alcohols (Method B) 
 
A mixture of 1 (435 mg, 1 mmol), Ph3P (393 mg, 1.5 mmol) and corresponding alcohol (1.5 mmol) in 5 
ml of THF was stirred at room temperature until a homogeneous solution was formed. After DEAD (0.24 
ml, 1.5 mmol) was added in one portion, the stirring was continued at ambient temperature. The reaction 
was monitored by TLC (silica gel, CH2Cl2-EtOH = 97:3). If the conversion of 1 was not completed after 
20h, the additional portions of reagents (Ph3P, alcohol and DEAD) in above indicated quantities were 
added to achieve full conversion of 1. After 4-5 h, the reaction mixture was evaporated and the residue 
was applied to column chromatography (silica gel, CH2Cl2-EtOH = 97:3). Partially purified compound 
was dissolved in 4M PrNH2 in MeOH solution (50 mmol) and was left for 24 h, after which the mixture 
was evaporated and the residue was applied to column chromatography. The product was eluted with 
CH2Cl2-EtOH (9:1 v/v) mixture. 
 
4.6.1. N
6
-(4-Hydroxy-2-butynyl)adenosine (3d) 
The yield of 3d was 203 mg (61%, white powder); Rf 0.13 (CH2Cl2- EtOH, 9:1). mp 160-162
o
C (EtOH - 
H2O). 
1
H NMR (400 MHz, DMSO-d6):  = 3.56 (ddd, 1H, J5′b,5′a = 11.9, J5′b,4′ = 4.1,  J5′b,OH = 7.0, H-5′b), 
3.68 (ddd, 1H, J5′a,5′b = 12.0, J5′a,4′ = 3.6, J5′a,OH = 4.6, H-5′a), 3.97 (ddd, 1H, J4′,5′b = 4.1,  J4′,5′a = 3.6,  J4′,3′ 
= 2.8, H-4′), 4.02 (dt, 2H, 5J = 1.7, 3JCH-OH = 5.8, OCH2C≡), 4.15 (ddd, 1H,  J3′,4′ = 2.8, J3′,2′ = 5.1, J3′,OH = 
4.8, H-3′), 4.32 (br s, 2H,  NCH2C≡, H-3′), 4.60 (ddd, 1H, J2′,3′ = 5.1, J2′,1′ = 6.0, J2′,OH = 6.2, H-2′), 5.10 
(t, 
3
JHO-CH = 5.8, ω-OH, exchangeable with D2O), 5.17 (d, 1H, JOH,3′ = 4.8, 3′-OH, exchangeable with 
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D2O), 5.34 (dd, 1H, JOH,5′b = 7.0, JOH,5′a = 4.6, 5′-OH, exchangeable with D2O), 5.43 (d, 1H, JOH,2′ = 6.2, 
2′-OH, exchangeable with D2O), 5.90 (d, 1H, J1′,2′ = 6.0, H-1′), 8.14 (br s, 1H, NH, exchangeable with 
D2O), 8.27 (s, 1H, H-2), 8.38 (s, 1H, H-8). 
13
C NMR (100 MHz, DMSO-d6): δ = 29.48 (CH2N), 49.12 
(CH2OH), 61.70 (C-5'), 70.67 (C-3'), 73.66 (C-2'), 81.41 (C≡), 81.73 (C≡), 85.96 (C-4'), 88.04 (C-1'), 
119.94 (C-5), 140.21 (C-8), 148.83 (C-4), 152.35 (C-2), 154.06 (C-6). MS (APCI): m/z [M+H
+
] 
calculated [C14H18N5O5] 336.13, found 336.18; m/z [M-H
-
+HCOOH] calculated [C15H18N5O7] 380.12, 
found 380.14. 
 
4.6.2. N
6
-(Z)-(4-Hydroxy-2-butenyl)adenosine (3e) 
The yield of 3e was 141 mg (42%, white powder); Rf 0.43 (CH2Cl2-EtOH, 9:1). mp 159-160
o
C (EtOH - 
H2O). 
1
H NMR (400 MHz, DMSO-d6): δ = 3.55 (ddd, 1H, J5′b,5′a = 12.0, J5′b,4′ = 3.6, J5′b,OH = 7.2, H-5′b), 
3.67 (ddd, 1H, J5′a,5′b = 12.1, J5′a,4′ = 3.8, J5′a,OH = 4.6, H-5′a), 3.96 (ddd, 1H, J4′,5′b = 3.6, J4′,5′a = 3.8, J4′,3′ = 
2.8, H-4′), 4.07-4.23 (m, 5H, overlapping OCH2C=, NCH2C=, H-3′), 4.60 (ddd, 1H, J2′,3′ = 4.9, J2′,1′ = 6.0, 
J2′,OH = 6.2, H-2′), 4.71 (t, J = 5.3, ω-OH, exchangeable with D2O), 5.15 (d, 1H, JOH,3′ = 4.6, 3′-OH, 
exchangeable with D2O), 5.37 (dd, 1H, JOH,5′b = 7.2, JOH,5′a = 4.6, 5′-OH, exchangeable with D2O), 5.41 
(d, 1H, JOH,2′ = 6.2, 2′-OH, exchangeable with D2O), 5.88 (d, 1H, J1′,2′ = 6.0, H-1′), 7.91 (br s, 1H, NH, 
exchangeable with D2O), 8.20 (s, 1H, H-2), 8.34 (s, 1H, H-8). 
13
C NMR (100 MHz, DMSO-d6): δ = 37.86 
(CH2N), 57.70 (CH2OH), 62.28 (C-5'), 71.26 (C-3'), 74.29 (C-2'), 86.64 (C-4'), 88.85 (C-1'), 119.83 (C-
5), 127.99 (CH=), 132.56 (CH=), 140.75 (C-8), 148.68 (C-4), 153.19 (C-2), 155.07 (C-6). MS (APCI): 
m/z [M+H
+
] calculated [C14H20N5O5] 338.13, found 338.20; m/z [M-H
-
+HCOOH] calculated 
[C15H20N5O7] 382.12, found 382.15. 
 
4.6.3. N
6
-Geranyladenosine (3f) 
The yield of 3f was 155 mg (39%) as a white powder; Rf 0.13 (CH2Cl2-EtOH, 97:3). mp 137-140
o
C (with 
decomposition). 
1
H NMR (400 MHz, DMSO-d6): δ = 1.54 (s, 3H, CH3), 1.59 (s, 3H, CH3), 1.70 (s, 3H, 
CH3), 1.92-1.99 (m, 2H, CH2CH2CH=), 2.00-2.08 (m, 2H, CH2CH2CH), 3.55 (ddd, 1H, J5′b,4′ = 3.6, J5′b,5′a 
= – 12.0, JOH,5′b = 7.3, H5'b), 3.68 (ddd, 1H, J5′a,5′b = 12.0, J5′a,4′ = 3.6, JOH,5′a = 4.6, H5'a), 3.96 (q, 1H, J4′,3′ 
= 3.6, J4′,5′a = 3.6, J4′,5′b = 3.6 Hz, H4'), 4.09 (br s, 2H, NHCH2), 4.15 (ddd, 1H, J3′,2′ = 5.2, J3′,4′ = 3.6, JOH,3′ 
= 4.6, H3'), 4.60 (ddd, 1H, J2′,1′ = 6.1, J2′,3′ = 5.2, JOH,2′ = 6.2, H2'), 5.06 (tt, 1H, JCH-CH2 = 7.0, JCH-Me = 1.4 
(trans) CHCMe2), 5.13 (d, 1H, JOH,3′ = 4.6, 3'OH, exchangeable with D2O), 5.31 (br. t, JCH-CH2 = 6.5 Hz,  
NHCH2CH), 5.36 (dd, 1H, J5′a,5′b = 12.0, JOH,5′b  = 7.2 Hz, JOH,5′a  = 4.6 Hz, 5'OH, exchangeable with D2O), 
5.39 (d, 1H, JOH,2′ = 6.2 Hz, 2'OH, exchangeable with D2O), 5.88 (d, 1H, J1′,2′ = 6.1 Hz, H1'), 7.84 (br s, 
1H, NH), 8.19 (s, 1H, H8), 8.32 (s, 1H, H2). 
13
C NMR (100 MHz, DMSO-d6): δ = 16.12, 17.48, 25.38, 
25.94, (CH2, CH2, CH3, CH3, CH3), 37.68 (NHCH2), 61.63 (C5'), 70.65 (C3'), 73.48 (C2'), 85.84 (C4'), 
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87.94 (C1'), 119.75 (C5), 121.73 (CH=), 123.91 (CH=), 130.75 (=C(Me)CH2), 136.64 (=CMe2), 139.59 
(C8), 148.30 (C4), 152.27 (C2), 154.35 (C6). HRMS: m/z [M+H]
+ 
calculated [C20H30N5O4] 404.2292, 
found 404.2284; m/z [M+Na]
+ 
calculated [C20H29N5O4Na] 426.2112, found 426.2102. 
 
4.6.4. N
6
-Neryladenosine (3g) 
The yield of 3g was 192 mg (48%) as a white powder; Rf 0.15 (CH2Cl2-EtOH, 97:3). mp 129-130
o
C (with 
decomposition). 
1
H NMR (400 MHz, DMSO-d6): δ = 1.58 (s, 3H, CH3), 1.64 (s, 3H, CH3), 1.67 (s, 3H, 
CH3), 2.03-2.16 (m, 4H, =C(Me)CH2CH2, CH2CH2CH=), 3.55 (ddd, 1H, J5′b,5′a = 12.2, J5′b,4′ = 3.5, J5′b,OH 
= 6.5, H5'b), 3.67 (ddd, 1H, J5′a,5′b = 12.2, J5′a,4′ = 3.5, J5′a,OH = 3.8, H5'a), 3.96 (q, 1H, J4′,3′ = 3.5, J4′,5′a = 
3.5, J4′,5′b = 3.5, H4'), 4.09 (br s, 2H, NHCH2), 4.15 (ddd, 1H, JOH,3′ = 4.6, J3′,2′ = 4.5, J3′,4′ = 3.5, H3'), 4.60 
(ddd, 1H, J2′,1′ = 6.1, J2′,3′ = 4.5, JOH,2′ = 6.3, H2'), 5.10-5.16 (m, 2H, overlapping 3'OH, CHCMe2), 5.31 
(br. t, JCH-CH2 = 6.6, NHCH2CH), 5.35 (dd, 1H, JOH,5′b  = 6.5, JOH,5′a  = 3.8, 5'OH, exchangeable with D2O), 
5.38 (d, 1H, JOH,2′ = 6.3 Hz, 2'OH, exchangeable with D2O), 5.88 (d, 1H, J1′,2′ = 6.1, H1'), 7.80 (br s, 1H, 
NH), 8.18 (s, 1H, H8), 8.32 (s, 1H, H2). 
13
C NMR (100 MHz, DMSO-d6): δ = 17.52, 23.09, 25.48, 26.08, 
31.67, (CH2, CH2, CH3, CH3, CH3), 37.36 (NHCH2), 61.67 (C5'), 70.64 (C3'), 73.50 (C2'), 85.88 (C4'), 
87.95 (C1'), 119.80 (C5), 122.68 (CH=), 124.05 (CH=), 131.07 (=C(Me)CH2), 136.85 (=CMe2), 139.64 
(C8), 148.30 (C4), 152.29 (C2), 154.39 (C6). HRMS: m/z [M+H]
+ 
calculated [C20H30N5O4] 404.2292, 
found 404.2286; m/z [M+Na]
+ 
calculated [C20H29N5O4Na] 426.2112, found 426.2105. 
 
4.6.5. N
6
-[(S)-(-)-Perillyl]-adenosine (3h) 
The yield of 3h was 241 mg (60%) as a white powder; Rf 0.11 (CH2Cl2-EtOH, 97:3). mp 158-160
o
C (with 
decomposition). 
1
H NMR (400 MHz, DMSO-d6): δ = 1.32–1.45 (m, 1H, H-perillyl), 1.68 (s, 3H, CH3-
perillyl), 1.71–1.91 (m, 2H, CH2-perillyl), 1.98–2.13 (m, 4H, 2×CH2-perillyl), 3.55 (dd, 1H, J5′b,5′a = 12.1, 
J5′b,4′ = 3.2, H5'b), 3.68 (dd, 1H, J5′a,5′b = 12.1 J5′a,4′ = 3.4, H5'a), 3.96 (ddd, 1H, J4′,3′ = 3.3, J4′,5′a = 3.4, J4′,5′b 
= 3.2, H4'), 4.03 (br.s, 2H, NHCH2), 4.12–4.18 (m, 1H, H3'), 4.62 (dd, 1H, J2′,1′ = 6.1, J2′,3′ = 5.2, H2'), 
4.68 (s, 2H, C(CH3)=CH2 - perillyl), 5.13 (br s, 1H, 3'OH, exchangeable with D2O), 5.43–5.30 (m, 2H, 
overlapping 5'OH, =CHCH2 - perillyl), 5.53 (br s, 1H, 2'OH, exchangeable with D2O), 5.88 (d, 1H, J1′,2′ = 
6.1, H1'), 7.89 (br s, 1H, NH), 8.19 (s, 1H, H8), 8.34 (s, 1H, H2). 
13
C NMR (100 MHz, DMSO-d6): δ = 
20.54, 26.57, 27.06, 29.81, (CH2, CH2, CH2, CH3), 40.52 (CHC(Me)=), 44.53 (NHCH2), 61.65 (C5'), 
70.63 (C3'), 73.42 (C2'), 85.88 (C4'), 87.94 (C1'), 108.77 (CH(Me)C=CH2), 119.68 (C5), 120.23 (=CH), 
134.77 (C(Me)=), 139.67 (C8), 148.32 (C4), 149.25 (NHCH2C=), 152.28 (C2), 154.68 (C6). HRMS: m/z 
[M+H]
+ 
calculated [C20H28N5O4] 402.2136, found 402.2135; m/z [M+Na]
+ 
calculated [C20H27N5O4Na] 
424.1955, found 424.1948. 
 
4.6.6. N
6
-[(1R)-(-)-Myrtenyl]-adenosine (3i) 
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The yield of 3i was 130 mg (33%) as white foam; Rf 0.11 (CH2Cl2-EtOH, 97:3). mp 168-169
o
C. 
1
H NMR 
(400 MHz, DMSO-d6): δ = 0.76 (s, 3H, CH3-myr), 1.10 (d, 1H, J = 8.4, H-myrtenyl), 1.22 (s, 3H, CH3-
myrtenyl), 2.26–2.00 (m, 4H, myrtenyl), 2.34 (dt, 1H, JCHaHb = 8.4, JCHa-CH1 = JCHa-CH2 = 5.7, CHaHb-
myrtenyl), 3.55 (ddd, 1H, J5′b,5′a = 12.1, J5′b,4′ = 3.7 Hz, JOH,5′b = 7.3, H5'b), 3.67 (ddd, 1H, J5′a,5′b = 12.1, 
JOH,5′a = 4.3, J5′a,4′ = 3.7, H5'a), 3.96 (td, 1H, J4′,3′ = 3.4, J4′,5′a = 3.7, J4′,5′b = 3.7, H4'), 4.07 (br.s, 2H, 
NHCH2), 4.14 (ddd, 1H, J3′,2′ = 4.7, J3′,4′ = 3.7, JOH,3′ = 4.6, H3'), 4.62 (ddd, 1H, J2′,1′ = 6.3 Hz, J2′,3′ = 4.7 
Hz, JOH,2′ = 6.2 Hz, H2'), 5.13 (d, 1H, JOH,3′ = 4.6 Hz, 3'OH, exchangeable with D2O), 5.32-5.38 (m, 2H, 
overlaping =CH-myrtenyl,  5'OH), 5.39 (d, 1H, JOH,2′ = 6.2 Hz, 2'OH), 5.88 (d, 1H, J1′,2′ = 6.3 Hz, H1'), 
7.83 (br s, 1H, NH), 8.17 (s, 1H, H8), 8.32 (s, 1H, H2). 
13
C NMR (100 MHz, DMSO-d6): δ = 20.89, 
26.04, 30.61, 31.02, 37.61, 43.29, (myrtenyl), 43.79 (NHCH2), 61.65 (C5'), 70.63 (C3'), 73.40 (C2'), 
85.87 (C4'), 87.88 (C1'), 116.41 (=CHCH2–), 119.55 (C5), 139.61 (C8), 145.30 (NHCH2C=), 148.50 
(C4), 152.20 (C2), 154.65 (C6). HRMS: m/z [M+H]
+ 
calculated [C20H28N5O4] 402.2136, found 402.2133; 
m/z [M+Na]
+ 
calculated [C20H27N5O4Na] 424.1955, found 424.1946. 
 
4.6.7. N
6
-(Cyclopropylmethyl)adenosine (3j) 
The yield of 3j was 110 mg (36%) as a white powder; Rf = 0.08 (CH2Cl2-EtOH, 97:3). mp 176-177
o
C. 
1
H 
NMR (400 MHz, DMSO-d6): δ = 0.27 (td, 2H, JCH2CH2 = 5.8 Hz, JCH2CH = 4.2 Hz, CH2-cyclopropyl), 0.41 
(td, 2H, JCH2CH2 = 6.0 Hz, JCH2CH = 4.2 Hz, CH2-cyclopropyl), 1.21–1.08 (m, 1H, NHCH2CH), 3.17 (d, 
1H, JOH,2′ = 5.5 Hz, 2'OH), 3.37 (br s, 1H, 3'OH, exchangeable with D2O), 3.55 (ddd, 1H, J5′b,4′ = 3.5 Hz, 
J5′b,5′a = 12.0 Hz, JOH,5′b = 6.8 Hz, H5'b), 3.68 (ddd, 1H, J5′a,4′ = 4.0 Hz, J5′a,5′b = 12.0 Hz, JOH,5′a = 4.9 Hz, 
H5'a), 3.95 (ddd, 1H, J4′,3′ = 7.2 Hz, J4′,5′a = 4.0 Hz, J4′,5′b = 3.5 Hz, H4'), 4.15 (dd, J3′,2′ = 4.7 Hz, J3′,4′ = 7.4 
Hz, H3'), 4.51 (dd, 1H, JOH,5′a = 4.9 Hz, JOH,5′b = 6.8 Hz, 5'OH), 4.61 (ddd, 1H, J2′,1′ = 6.0 Hz, J2′,3′ = 4.7 
Hz, JOH,2′ = 5.5 Hz, H2'), 5.48–5.34 (m, 2H, NHCH2), 5.90 (d, 1H, J1′,2′ = 6.0 Hz, H1'), 7.88 (br s, 1H, 
NH), 8.18 (s, 1H, H8), 8.33 (s, 1H, H2). 
13
C NMR (100 MHz, DMSO-d6): δ =3.21 (CH2, CH2), 11.13 
(CH2CH), 43.97 (NHCH2), 61.66 (C5'), 70.63 (C3'), 73.46 (C2'), 85.88 (C4'), 87.96 (C1'), 119.68 (C5), 
139.63 (C8), 148.39 (C4), 152.29 (C2), 154.64 (C6). HRMS: m/z [M+H]
+ 
calculated [C14H20N5O4] 
322.1509, found 322.1510; m/z [M+Na]
+ 
calculated [C14H19N5O4Na] 344.1329, found 344.1326. 
 
4.6.8. N
6
-(Tetrahydropyran-2-methyl)-adenosine (3k) 
The yield of 3e was 187 mg (51%) as a white powder; Rf = 0.02 (CH2Cl2- EtOH, 97:3). mp 145-147
o
C. 
1
H NMR (400 MHz, DMSO-d6): δ = 1.85–1.13 (m, 6H, tetrahydropyran), 3.37–3.25 (m, 1H, 
tetrahydropyran, overlaping with D2O), 3.50–3.40 (m, 1H, tetrahydropyran), 3.51 (br s, 2H, NHCH2), 
3.57 (ddd, 1H, J5′b,4′ = 3.6 Hz, J5′b,5′a = – 12.1 Hz, JOH,5′b = 6.9 Hz, H5'b), 3.68 (ddd, 1H, J5′a,4′ = 3.8 Hz, 
J5′a,5′b = – 12.1 Hz, JOH,5′a = 4.4 Hz, H5'a), 3.90–3.83 (m, 1H, tetrahydropyran), 3.96 (ddd, 1H, J4′,3′ = 3.4 
Hz, J4′,5′a = 3.4 Hz, J4′,5′b = 3.4 Hz, H4'), 4.15 (ddd, 1H, J3′,2′ = 4.7 Hz, J3′,4′ = 3.2 Hz, JOH,3′ = 4.6 Hz, H3'), 
16 
 
4.61 (dd, 1H, J2′,1′ = 6.0 Hz, J2′,3′ = 4.7 Hz, JOH,2′ = 6.2 Hz, H2'), 5.13 (d, 1H, JOH,3′ = 4.6 Hz, 3'OH), 5.34 
(dd, 1H, JOH,5′b  = 6.9 Hz, JOH,5′a  = 4.4 Hz, 5'OH), 5.39 (d, 1H, JOH,2′ = 6.2 Hz, 2'OH), 5.88 (d, 1H, J1′,2′ = 
6.1 Hz, H1'), 7.59 (br s, 1H, NH), 8.20 (s, 1H, H8), 8.34 (s, 1H, H2). 
13
C NMR (100 MHz, DMSO-d6): δ 
= 29.07, 25.65, 22.59 (tetrahydropyran), 44.67 (NHCH2), 61.64 (C5'), 67.26 (tetrahydropyran), 70.61 
(C3'), 73.47 (C2'), 75.48 (NHCH2CHO tetrahydropyran), 85.87 (C4'), 87.94 (C1'), 119.67 (C5), 139.76 
(C8), 148.32 (C4), 152.25 (C2), 154.64 (C6). HRMS: m/z [M+H]
+ 
calculated [C16H24N5O5] 366.1772, 
found 366.1768; m/z [M+Na]
+ 
calculated [C16H23N5O5Na] 388.1591, found 388.1586. 
 
4.7. N
6
-Isopentenyladenine (4a) 
Compound 4a was obtained by the enzymatic phosphorolysis of 3a in the presence of E. Coli 
Recombinant Purine Nucleoside Phosphorylase (PNP) in KH2PO4 buffer (pH 7.5) [10]. 
The yield of 4a was 15 mg (50%) as a white powder; Rf 0.43 (CH2Cl2-EtOH, 9:1). mp
 
218-220
o
C. 
1
H 
NMR (400 MHz, DMSO-d6): δ = 1.67 (s, 3H, Me), 1.70 (s, 3H, Me), 4.08 (br s, 1H, NCH2), 5.31 (s, 1H, 
HC=C), 7.55 (br s, 1H, NH), 8.04 (s, 1H, H-2), 8.16 (s. 1H, H-8), 12.84 (br s, 1H, NH). 
 
4.8. Procedure for preparation of nucleobases 4b-c by acid hydrolysis of nucleosides 3b-c 
The solution of corresponding nucleoside 3b-c (0.2 mmol) in 0.5M НСl (2.5 ml, 1.26 mmol) was stirred 
at 100°С for 8 h. The reaction was monitored by TLC. (acetonitrile - 25% ammonia, 9:1). When the traces 
of initial nucleoside 3 had disappeared, the reaction was cooled down and neutralized to pH 7 with 
concentrated NH3. The resulting precipitate was filtered, washed with cold water (2×5 ml), acetone (2×5 
ml) and dried in vacuum over P2O5.  
 
4.8.1. N
6
-Allyladenine (4b) 
The yield of 4b was 26 mg (70%) as a white powder. Rf 0.45 (acetonitrile-ammonia, 9:1). mp 223-224
 o
C.
 
1
H NMR (400 MHz, DMSO-d6): δ = 4.16 (br s, 2Н, NСH2), 5.06 (d, 1H, 
3
J = 9.5 Hz, С=СН-cis), 5.17 (d, 
1H, 
3
J = 17 Hz, С=СН-trans), 5.93-6.00 (m, 1H, -CH=СH2), 7.71 (br s, 1H, H-6), 8.07 (s, 1H, H-2), 8.17 
(s, 1H, H-8), 12.87 (br s, 1H, 9-NH).
 13
C NMR (100 MHz, DMSO-d6): δ = 41.94 (CH2), 114.96 (=CH), 
135.91 (=CH2), 138.73 (C-8), 149.83 (C-4), 152.30 (C-2), 154.26 (C-6).
 
 
4.8.2. N
6
-Propargyladenine (4c) 
The yield of 4c was 35 mg (94%) as a white powder; Rf 0.67 (acetonitrile – 25% ammonia, 9:1).
 
 mp 255
 
o
C (with decomposition). 
1
H NMR (400 MHz, DMSO-d6): δ = 3.01 (s, 1H, ≡CH), 4.30 (s, 2H, CH2), 7.92 
(br s, 1H, H-9), 8.12 (s, 1H, H-2), 8.24 (s, 1H, H-8), 12.96 (br s, 1H, NH). 
13
C NMR (100 MHz, DMSO-
17 
 
d6): δ = 29.26 (CH2N), 72.38 (HC≡), 82.01 (-C≡), 117.95 (C-5), 139.51 (C-8), 147.58 (C-4), 152.16 (C-
2), 153.23 (C-6). 
 
4.9. N
6
-Acetyl-N
6
-(hex-5-en-2-ynyl)-2′,3′,5′-tri-O-acetyladenosine (5) 
The reaction was carried out in N2 atmosphere using standard Schlenk technique. A mixture of 2c (500 
mg, 1.06 mmol), CuCl (105 mg, 1.06 mmol), K2CO3 (292 mg, 2.12 mmol), Bu4NBr (34 mg, 0.106 
mmol), CH2=CHCH2Br (0.1 ml, 1.16 mmol) and DMF (5 ml) was stirred at room temperature in N2 
atmosphere for 14 h. Subsequently, the flask was opened and stirring was continued for an additional 8 h. 
The mixture was diluted with AcOEt (150 ml) and washed successively with water (30 ml) and 0.1 M 
water solution of disodium EDTA (3x30 ml). The organic layer was separated, dried over Na2SO4 and 
evaporated. The residue was applied to column chromatography on silica gel. 
The yield of 5 was 477 mg (88 %) as a foam; Rf 0.47 (CH2Cl2-EtOH, 25:1). 
1
H NMR (400 MHz, CDCl3): 
δ = 2.10 (s, 3H, AcO), 2.13 (s, 3H, AcO), 2.16 (s, 3H, AcO), 2.37 (s, 3H, AcN), 2.80-2.86 (m, 3J = 5.1, 4J 
= 2 and 1.6, 
5
J = 2.2, 2Н, ≡ССН2С=), 4.40 (dd, 1H, J5′b,5′a = 12.9, J5′b,4′ = 5.3, H-5′b), 4.48 (dd, 1H, J5′a,5′b 
= 12.9, J5′a,4′ = 3.1, H-5′a), 4.48 (ddd, 1H, J4′,5′b = 5.3, J5′a,4′ = 3.1, J4′,3′ = 4.7, H-4′), 4.97 (ddt, 1Н, 
2
J = 1.7, 
3
J = 10, 
4
J = 1.6, С=СН-trans), 5.06 (ddt, 1Н, 2J = 1.7, 3J = 17.1, 4J = 2, С=СН-cis), 5.10 (t, 2Н, 5J = 2.2, 
NCH2), 5.65 (ddt, 1Н, 
3
J = 5.1, 10 and 17.1, СН2СН=С), 5.69 (dd, 1H, J3′,4′ = 4.7, J3′,2′ = 5.6, H-3′), 5.97 
(dd, 1H, J2′,3′ = 5.6, J2′,1′ = 5.0, H-2′), 6.25 (d, 1H, J1′,2′ = 5.0, H-1′), 8.20 (s, 1H, H-2), 8.81 (s, 1H, H-8). 
13
C NMR (100 MHz, CDCl3): δ = 20.50 (AcO), 20.62 (AcO), 20.85 (AcO), 23.08 (NAc), 23.08 (CH2), 
37.06 (NCH2), 63.11 (C-5'), 70.65 (C-3'), 70.77 (≡C-), 73.28 (C-2'), 77.79 (-C≡), 80.54 (C-4'), 86.90 (C-
1'), 116.02 (-C=), 132.32 (=CH2), 138.50 (C-4), 142.19 (C-8), 152.34 (C-2), 152.72 (C-6), 169.47 (CO), 
169.67 (CO), 170.39 (CO), 170.45 (CO). MS (APCI): m/z [M+H]
+ 
calculated [C24H28N5O] 514.19, found 
514.75. 
 
4.10. N
6
-Acetyl-N
6
-(6-Methylhept-5-en-2-ynyl)-2′,3′,5′-tri-O-acetyladenosine (6) 
The reaction was carried out in N2 atmosphere using standard Schlenk technique. To a stirred mixture of 
2c (500 mg, 1.06 mmol), CuCl (105 mg, 1.06 mmol), K2CO3 (292 mg, 2.12 mmol) and Bu4NBr (34 mg 
0.106 mmol) in DMF (5 ml), 80% solution of isopenthenyl bromide in toluene (0.274 ml, 2.33 mmol) was 
added in one portion. The reaction mixture was stirred at room temperature for 48 h, after which it was 
diluted with AcOEt (150 ml) and washed successively with water (30 ml) and 0.1 M water solution of 
disodium EDTA (3x30 ml). The extract was dried over Na2SO4 and evaporated. The residue was applied 
to column chromatography on silica gel. 
The yield of 6 was 417 mg (72 %) as a foam; Rf 0.5 (CH2Cl2-EtOH, 25:1). 
1
H NMR (400 MHz, CDCl3): δ 
= 1.49 (s, 3Н, Ме), 1.62 (d, 3Н, 4J = 1, Ме), 2.10 (s, 3H, AcO), 2.13 (s, 3H, AcO), 2.16 (s, 3H, AcO), 
2.36 (s, 3H, AcN), 2.74 (m, 2Н, 3J = 6.9, 5J = 2.2, ≡ССН2С=), 4.39 (dd, 1H, J5′b,5′a = 12.9, J5′b,4′ = 5.4, H-
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5′b), 4.47 (dd, 1H, J5′a,5′b = 12.9, J5′a,4′ = 3, H-5′a), 4.48 (ddd, 1H, J4′,5′b = 5.4, J5′a,4′ = 3, J4′,3′ = 4.7, H-4′), 
5.00 (m, 1Н, 3J = 10, 4J = 1, СН2СН=С), 5.05 (t, 2Н, 
5
J = 2.2, NCH2), 5.69 (dd, 1H, J3′,4′ = 4.7, J3′,2′ = 5.6, 
H-3′), 5.97 (dd, 1H, J2′,3′ = 5.6, J2′,1′ = 5.1, H-2′), 6.25 (d, 1H, J1′,2′ = 5.1, H-1′), 8.20 (s, 1H, H-2), 8.81 (s, 
1H, H-8).
 13
C NMR (100 MHz, CDCl3): δ = 17.86 (Me), 20.33 (AcO), 20.44 (AcO), 20.66 (AcO), 24.21 
(NAc), 25.54 (Me), 45.56 (NCH2), 45.56 (CH2), 62.95 (C5'), 70.63 (≡C-), 70.67 (-C≡), 70.46 (C-3'), 
73.12 (C-2'), 80.30 (C-4'), 86.81 (C-1'), 120.10 (-CH=), 127.55 (C-5), 135.75 (CMe2), 142.15 (C-8), 
152.19 (C-2), 152.48 (C-4), 153.83 (C-6), 169.34 (CO), 169.52 (CO), 170.21 (CO), 171.15 (CO). MS 
(APCI): m/z [M+H]
+ 
calculated [C26H31N5O8] 542.22, found 542.22. 
 
4.11. N
6
-(Hex-5-en-2-ynyl)adenosine (7) 
Compound 5 (1.2 g, 2.34 mmol) was dissolved in 7M NH3 in MeOH (6.7 ml, 46.8 mmol) and the 
solution was left for 48 h at room temperature. The reaction mixture was evaporated and the residue was 
treated with 5ml of cold MeOH. The solid was filtered, washed with MeOH (5 ml) and dried in vacuum 
over Р2О5. 
The yield of 7 was 609 mg (75%) as a white powder; Rf 0.28 (CH2Cl2-EtOH, 9:1). mp 136-138
o
C. 
1
H 
NMR (400 MHz, DMSO-d6 + D2O): δ = 2.95 (m, 2H, 
3
J = 5, 
4
J = 1.4 and 1.7, -CH2CH=), ), 3.56 (dd, 1H, 
J5′a,5′b = 12.5, J5′a,4′ = 3.3, H-5′a), 3.67 (dd, 1H, J5′b,5′a = 12.5, J5′b,4′ = 3.4, H-5′b, 3.97 (ddd, 1H, J4′,5′b = 3.4, 
J4′,5′a = 3.3, J4′,3′ = 2.9, H-4′), 4.15 (dd, 1H, J3′,4′ = 2.9, J3′,2′ = 5.3, H-3′), 4.31 (broad s, 2H, NCH2), 4.61 
(dd, 1H, J2′,3′ = 5.3, J2′,1′ = 6.0, H-2′), 5.05 (ddt, 1H, 
2
J = 1.7, 
3
J = 10, 
4
J = 1.7, -С=CH-trans), 5.26 (ddt, 
1H, 
2
J = 1.7, 
3
J = 17.3, 
4
J = 1.4, -С=CH-cis), 5.15 (d, 1H, 3′OH), 5.32 (dd, 1H, 5′OH), 5.42 (d, 1H, 
2′OH), 5.77 (ddt, 1H, 3J = 5, 10 and 17.3, СН2CH=С), 5.90 (d, 1H, J1′,2′ = 6.0, H-1′), 8.18 (br s, 1H, NH), 
8.27(br s, 1H, H-2), 8.39 (s, 1H, H-8). 
13
C NMR (100 MHz, CDCl3): δ = 22.26 (CH2), 29.44 (NCH2), 
61.58 (C-5'), 70.55 (C-3'), 73.50 (C-2'), 78.12 (≡C-), 80.34 (-C≡), 85.81 (C-4'), 87.88 (C-1'), 115.79 (-
CH=), 119.80 (C-5), 132.95 (=CH2), 140.02 (C-8), 148.72 (C-4), 152.19 (C-2), 153.97 (C-6). MS (APCI): 
m/z [M+H]
+ 
calculated [C16H20N5O4] 346.14, found 346.25. 
 
4.12. N
6
-(6-Methylhept-5-en-2-ynyl)adenosine (8) 
Compound 6 (1 g, 1.9 mmol) was dissolved in 7M NH3 in MeOH (5.6 ml, 40.7 mmol) and the solution 
was left for 48 h at room temperature. The reaction mixture was evaporated and the residue was treated 
with 5 ml of cold MeOH. The solid was filtered, washed with MeOH (5 ml) and dried in vacuum over 
Р2О5. 
The yield of 8 was 510 mg (76%) as a white powder; Rf 0.67 (CH2Cl2-EtOH, 4:1). mp 128-130
o
C. 
1
H 
NMR (400 MHz, DMSO-d6 + D2O): δ = 1.55 (s, 3H, Ме), 1.64 (d, 3H, 
4
J = 1, Ме), 2.85 (d, 2H, 3J = 6.8, 
С-CH2-CH=), 3.55 (dd, 1H, J5′a,5′b = 12.2, J5′a,4′ = 3.5, H-5′a), 3.65 (dd, 1H, J5′b,5′a = 12.2, J5′b,4′ = 3.4, H-
5′b), 3.98 (ddd, 1H, J4′,5′b = 3.4, J4′,5′a = 3.5, J4′,3′ = 2.8, H-4′), 4.14 (dd, 1H, J3′,4′ = 2.8, J3′,2′ = 4.9, H-3′), 
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4.25 (br s, 2H, NCH2), 4.56 (dd, 1H, J2′,3′ = 4.9, J2′,1′ = 6.2, H-2′), 5.09 (m, 1H, 
3
J = 6.8, 
4
J = 1, 
СН2СН=С) 5.86 (d, 1H, J1′,2′ = 6.2, H-1′), 8.23 (br s, 1H, H-2), 8.31 (с, 1H, H-8). 
13
C NMR (100 MHz, 
DMSO-d6): δ = 17.16 (Me), 25.09 (Me), 29.07 (CH2), 29.38 (NCH2), 61.64 (C5'), 70.54 (C-3'), 70.61 
(≡C-), 73.42 (-C≡), 73.51 (C-2'), 85.84 (C-4'), 87.89 (C-1'), 105.06 (-CH=), 119.09 (C-5), 139.85 (CMe2), 
143.20 (C-8), 149.05 (C-4), 152.33 (C-2), 156.13 (C-6). MS (APCI): m/z [M+H]
+ 
calculated 
[C18H24N5O4] 374.41, found 374.30. 
 
5. Antiviral assays 
 
RD (rhabdomyosarcoma) cells were obtained from the European Collection of Cell Cultures and were 
maintained in minimal essential medium (Gibco) supplemented with 10% heat-inactivated fetal bovine 
serum (FBS), 1% sodium bicarbonate (Gibco) and 1% L-glutamine (Gibco). Cells were grown at 37°C 
and 5% CO2. EV71 strains that originated from Taiwan were a generous gift from Dr. Shih-Cheng Chang 
(Chang Gung University, Taoyuan, Taiwan). Strain H08300 461 #812 was acquired from National 
Collection of Pathogenic Viruses (NCPV). Strain 11316 was a kind gift from the National Institute for 
Public Health and the Environment (RIVM, The Netherlands). EV71 strain BrCr was kindly provided by 
F. van Kuppeveld (UMCU, The Netherlands). Poliovirus 3 was a gift from J. Martin 
(NIBSC,Hertfordshire, UK). All other viruses belonged to the virus collection of the Rega Institute for 
Medical Research 
The antiviral assay for HCV was essentially performed as described by Manfroni et al. [24] while that for 
chikungunya virus was performed as described by Gigante et al. [25]. The antiviral assay for EV7 was 
performed as described by Tijsma et al [26] Briefly, RD cells, grown to confluence in 96-well microtiter 
plates were infected with ~100 CCID50 of EV71 and were treated with a dilution series of the different 
compounds. Cultures were incubated for three days at 37°C (5% CO2) after which residual cell viability 
was quantified using an MTS readout method according to the manufacturers’ instructions (Promega). A 
similar assay setup was used for the other viruses, although with different cell lines (BGM cells for the 
polioviruses as well as echovirus 11, Vero cells for Coxsackievirus B3, and HeLa cells for the human 
rhinoviruses). 
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